# Causal Couture — Phase 5: Causal Evidence Interpretation and Decision Readiness

**Reporting week:** Week 11  
**Reporting period:** October 5–11, 2026  
**Project:** Causal Couture  
**Workstream:** Phase 5 — Causal Intelligence  
**Contribution type:** Methodology review, analytical design, and documentation  
**Implementation scope:** No new Python modules, endpoints, or frontend changes in this documentation update

## 1. Purpose

Causal Couture brings together fashion-retail sales, inventory, social engagement, and web-behavior data at a `date × SKU` level. Earlier project phases established data processing, descriptive scoring, scenario simulations, and an observational causal-analysis layer. The current causal question is:

> What is the causal effect of social engagement on subsequent product sales?

The Phase 5 analysis examines engagement at time *t* and sales on the next calendar day, using observed controls and a set of reliability diagnostics. Week 9 added a heuristic unobserved-confounding stress test; Week 10 added a reliability-reconciliation layer to organize the status and interpretation of those diagnostics.

**Week 11 focuses on what should happen after reliability results are assembled:** how an analyst should interpret agreements, contradictions, missing evidence, and limitations before communicating findings to a retailer. The aim is a documented interpretation framework, **not** an automated claim of causal certainty.

## 2. Why a separate interpretation framework is needed

A single effect estimate cannot communicate the full credibility of an observational analysis. Even a statistically stable estimate may be misleading if, for example, treatment and comparison conditions have poor overlap, product availability constrains sales, or an impossible-direction temporal placebo reveals residual structure.

Likewise, a diagnostic that fails to execute or has too little data is **unknown evidence**, not a passing result. A consolidated dashboard can make many outputs visible without explaining how they relate. This document proposes rules for reviewing them together while preserving their distinct methodological meanings.

The framework separates three questions:

1. **Execution:** Did each diagnostic run and return an interpretable result?
2. **Evidence:** What concern, if any, does each diagnostic raise about the observational estimate?
3. **Use:** What conclusions and next actions are justified by the evidence currently available?

These are separate judgments. Successful execution is not equivalent to favorable evidence; favorable diagnostics are not equivalent to experimental identification.

## 3. Diagnostic inventory and interpretation boundaries

| Component | What it helps assess | Interpretation boundary |
|---|---|---|
| Adjusted engagement-effect estimator | Association between engagement at *t* and next-day sales after available adjustment | Observational estimate; vulnerable to unmeasured confounding and model assumptions |
| Row-level bootstrap | Sensitivity of the estimate to observation-level resampling | Can underrepresent uncertainty when rows from the same SKU are dependent |
| SKU-cluster bootstrap | Uncertainty when repeated observations are resampled together by SKU | Depends on having enough independent SKU clusters; does not solve unmeasured confounding |
| Shuffled-treatment placebo | Whether a relationship persists when original treatment structure is disrupted | A weak placebo is reassuring only within the tested design; it does not prove causality |
| Temporal falsification | Whether future engagement appears associated with earlier sales | An impossible-direction association warns about residual temporal structure; absence is not proof |
| Treatment-overlap diagnostic | Whether engagement variation appears sufficient for comparison | Global variation is not a full conditional-positivity test |
| Stockout / inventory diagnostic | Whether low or absent stock may suppress observed sales | Cannot recover unobserved demand without additional assumptions or data |
| Model-specification robustness | Whether effect direction/magnitude changes with alternative controls | Stability across observed specifications cannot eliminate omitted-variable bias |
| Synthetic confounding sensitivity | Whether the estimate changes under hypothetical latent-factor stress | Heuristic stress test; not a formal causal bound or an estimate of actual hidden confounding |
| Week 10 reliability review | Which diagnostics ran, failed, or returned inconclusive evidence | Reconciles output; does not independently validate causal identification |

## 4. Proposed evidence classification

Each diagnostic should receive **two separate labels**:

**Execution status**
- **Available:** completed and returned an interpretable result.
- **Inconclusive:** ran but lacked enough data, variation, or eligible observations for interpretation.
- **Error:** failed because of a processing or implementation problem.
- **Not reviewed:** output has not yet been inspected.

**Evidence signal** (only when the output supports a judgment)
- **Reassuring within scope:** the specific diagnostic does not reveal a major warning.
- **Caution:** the diagnostic indicates a limitation that could materially affect interpretation.
- **Mixed:** some parts of the diagnostic are reassuring while others raise concerns.
- **Undetermined:** no defensible evidence judgment can be made.

These are **qualitative review labels**, not a numerical probability that the causal effect is true. A diagnostic with execution status *Error* or *Inconclusive* must not be labeled *Reassuring within scope* by default.

## 5. How to reconcile conflicting findings

### 5.1 Row bootstrap versus SKU-cluster bootstrap

If the row-level confidence interval is narrow but the SKU-cluster interval is substantially wider, review the number of independent SKUs and the possibility of within-SKU dependence. Do not automatically choose the narrower interval. A cluster-bootstrap interval may be more relevant for repeated product observations, though it can also be unstable with too few clusters.

**Documentation action:** record both intervals, their methods, and whether each includes zero. If interval fields are missing or incompatible, mark the comparison undetermined rather than assuming agreement.

### 5.2 Primary estimate versus temporal placebo

A primary engagement estimate and a sizable impossible-direction placebo association can coexist. In that case, the placebo result raises concern about temporal confounding, shared trends, or specification problems. The primary estimate should be presented with a clear caution rather than suppressed or declared invalid automatically.

**Documentation action:** report the primary effect and placebo estimate with compatible units, and describe the temporal limitation. Do not treat a successfully estimated placebo as a passed placebo.

### 5.3 Specification stability versus synthetic confounding sensitivity

An effect may remain stable across observed-control specifications while changing direction under hypothetical hidden-confounder stress. These results are not necessarily contradictory: they test different vulnerabilities.

**Documentation action:** describe observed-specification stability separately from simulated-confounding sensitivity. A synthetic direction change is a sensitivity warning, **not** evidence that the synthetic confounder exists in real retail operations.

### 5.4 Favorable estimates versus stockout or overlap limitations

A positive estimated engagement effect does not override insufficient treatment overlap or inventory-constrained sales. These limitations affect whether comparisons and outcomes are meaningful.

**Documentation action:** make the overlap and inventory warnings visible beside the estimate, rather than hiding them in a technical appendix.

## 6. Decision-readiness framework — design, not deployed automation

The following categories describe **proposed analyst-facing interpretation**, not a newly implemented Week 11 API or automated decision engine.

| Review category | When to use it | Permitted next step |
|---|---|---|
| **Insufficient evidence for action** | Primary estimate unavailable, important diagnostics errored, or major data requirements unmet | Fix data or diagnostic issues; avoid using the estimate for decisions |
| **Analyst review required** | Material sensitivity, conflicting diagnostics, overlap concerns, or inventory limitations | Investigate assumptions and compare alternatives before making recommendations |
| **Exploratory interpretation only** | Results are available and no major warning is currently identified | Discuss patterns and plan further validation; do not claim proven causation |

No category constitutes approval for **automatic inventory purchasing, advertising spend changes, or pricing decisions**. A decision about operational action would require separate business constraints, cost-benefit evaluation, and stronger validation where feasible.

### Suggested communication language

**When findings are relatively stable:**
> The adjusted observational estimate was directionally stable across the diagnostics reviewed. This is reassuring within those tests, but unmeasured confounding and other identification assumptions remain unresolved.

**When findings are mixed:**
> The estimated relationship should be interpreted cautiously because one or more reliability checks raise concerns that are not resolved by the primary model.

**When evidence is incomplete:**
> The current analysis does not provide enough reliable diagnostic evidence to support a causal interpretation for business action.

These are wording templates. They should be used only after checking actual endpoint results.

## 7. Week 11 review procedure

This week’s contribution is the interpretation design and methodology documentation. To complete an empirical review later, an analyst can:

1. Run the existing `GET /phase5/causal-intelligence` endpoint with a valid unified daily-SKU CSV filename.
2. Inspect the Week 10 `reliability_review` section and underlying diagnostic outputs.
3. Record each component's execution status separately from its evidence signal.
4. Check for the four conflicts described in Section 5; do not infer agreement from missing fields.
5. Record a provisional interpretation category with supporting evidence and unresolved limitations.
6. Retain the actual response or a reproducible reference to the input dataset before making a quantitative claim.

**No empirical Week 11 result is asserted in this document.** The following table is intentionally unfilled until a real response has been inspected.

| Review item | Actual output / reference | Execution status | Evidence signal | Notes |
|---|---|---|---|---|
| Primary adjusted estimate | Not yet recorded | Not reviewed | Undetermined | |
| Row bootstrap | Not yet recorded | Not reviewed | Undetermined | |
| SKU-cluster bootstrap | Not yet recorded | Not reviewed | Undetermined | |
| Shuffled placebo | Not yet recorded | Not reviewed | Undetermined | |
| Temporal falsification | Not yet recorded | Not reviewed | Undetermined | |
| Overlap | Not yet recorded | Not reviewed | Undetermined | |
| Stockout / inventory | Not yet recorded | Not reviewed | Undetermined | |
| Model robustness | Not yet recorded | Not reviewed | Undetermined | |
| Synthetic confounding sensitivity | Not yet recorded | Not reviewed | Undetermined | |
| Week 10 reliability reconciliation | Not yet recorded | Not reviewed | Undetermined | |

## 8. Distinguishing the project's analytical layers

Causal Couture maintains a separation between:

- **Observed signal:** descriptive retail indicators and heuristic recommendations from observed data.
- **Scenario simulation:** hypothetical changes evaluated through the scenario model; these are not identified causal interventions.
- **Estimated causal effect:** an observational estimate subject to adjustment assumptions and reliability diagnostics.

Week 11's interpretation framework is designed specifically for the third layer. It should not turn descriptive scores or scenario outputs into causal evidence, and it should not equate an estimated engagement effect with a guaranteed sales lift.

## 9. Limitations and future implementation opportunities

This document defines a review framework but does not implement automated classification, an evidence decision engine, or a new API. Future implementation could add a machine-readable interpretation summary, explicit diagnostic-compatibility checks, and a UI that displays cautionary evidence beside effect estimates.

Further methodological work could examine formal sensitivity analysis, conditional overlap, dependence across products and dates, and stronger external validation. These are **future options**, not completed Week 11 features.

## 10. Week 11 contribution and outcome

Week 11 produced a documented **Causal Evidence Interpretation and Decision Readiness** framework for Causal Couture's Phase 5 reliability stack. It defines separate execution and evidence labels, establishes conservative rules for interpreting conflicting diagnostics, and proposes analyst-facing categories that avoid treating observational estimates as experimental proof.

This is a **documentation-only project contribution**. It continues Week 10's reliability-reconciliation work without modifying production code or claiming new empirical findings. The framework provides a basis for future review, implementation, and responsible communication of the project's causal results.
